Crinetics Pharmaceuticals Prices Public Offering of Common Stock at $45.95 Per Share

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a U.S.-based biopharmaceutical company specializing in therapies for endocrine diseases and related tumors, today announced the pricing of a public offering of its common stock. The company will sell **7,620,000 shares at $45.95 per share**, aiming to raise approximately **$350 million in gross proceeds before underwriting discounts and offering expenses.** Underwriters have a 30‑day option to buy up to an additional 1,143,000 shares of common stock. The offering is expected to close on or about January 8, 2026, subject to customary closing conditions. Crinetics plans to use the net proceeds — along with existing cash and investments — to support the commercial launch of PALSONIFY™, its recently FDA‑approved oral treatment for acromegaly, as well as research and development of other product candidates, funding of discovery programs, and for general corporate purposes. The company may also apply a portion of the proceeds toward in‑licensing, acquisitions, or investments in complementary technologies or assets, although no commitments currently exist. Joint bookrunning managers for the offering include Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler and Cantor, with Baird acting as lead manager. Crinetics’ pipeline includes additional therapeutic candidates addressing rare endocrine disorders including congenital adrenal hyperplasia, Cushing’s syndrome, and neuroendocrine tumors. #Crinetics #PublicOffering #BiotechFunding #PALSONIFY #SlimScan #GrowthStocks #CANSLIM